I have had the privilege of working with the exceptional team at Karmanos for the past 3 years and have seen firsthand their unprecedented level of compassion, commitment, and expertise when serving our patients.— Justin F. Klamerus, MD, MMM
Tweet this quote
Justin F. Klamerus, MD, MMM, has been appointed President of the Barbara Ann Karmanos Cancer Hospital, the clinical operation of Karmanos Cancer Institute in Detroit. The appointment was effective as of January 2017.
Dr. Klamerus will report directly to Gerold Bepler, MD, PhD, President and Chief Executive Officer of Karmanos Cancer Institute—1 of 47 National Cancer Institute–designated comprehensive cancer centers in the country. Dr. Klamerus assumes the role after serving as interim President since April 2016, following the departure of Margaret Dimond, PhD. He will oversee all clinical operations at Karmanos’ treatment locations in Detroit and Farmington Hills. He will also continue as Associate Professor of Oncology at Wayne State University School of Medicine.
Prior to being appointed President, Dr. Klamerus oversaw operations of the Karmanos Cancer Network—14 cancer centers, including 9 radiation centers throughout Michigan. He has served in various roles since joining the staff of Karmanos in early 2014, including Executive Vice President/Chief Quality Officer and Associate Center Director for Community Oncology.
“I have had the privilege of working with the exceptional team at Karmanos for the past 3 years and have seen firsthand their unprecedented level of compassion, commitment, and expertise when serving our patients,” said Dr. Klamerus. “I’m honored to serve as the next President of Karmanos Cancer Hospital, and I know…we will continue to provide high-quality, state-of-the-science cancer care with compassion, dignity, and determination, which will lead to the next standard of cancer care.”
Dr. Klamerus served as President and Medical Director of the McLaren Cancer Institute from 2012 to 2014 and Cancer Program Director at McLaren Northern Michigan from 2009 to 2012, where he also practiced medical oncology. At McLaren, Dr. Klamerus led cancer research operations, serving as principal investigator for cancer research studies. During his tenure, McLaren saw a fourfold increase in cancer research accruals.
A graduate of the College of Human Medicine at Michigan State University, Dr. Klamerus completed his residency and chief residency in internal medicine at The Ohio State University. He also served as Clinical Instructor of Internal Medicine and as a lecturer in the College of Medicine and Public Health at The Ohio State. Then, he attended Johns Hopkins University, where he completed a fellowship in medical oncology. Dr. Klamerus earned a Master of Medical Management degree from the Heinz College at Carnegie Mellon University. Currently, he is completing a management fellowship in health-system leadership in the General Electric Leadership Fellowship program of the Health Management Academy.
Dr. Klamerus is a member of ASCO, having served on several committees. He is also a member of the Steering Committee of the Michigan Oncology Quality Consortium. Dr. Klamerus has served as the Program Director of the Michigan Oncology Clinical Treatment Pathways Program, a clinical quality initiative of Blue Cross Blue Shield of Michigan. ■